229 cases of adverse drug reactions caused by Keke tablets

doi:10.19803/j.1672-8629.2022.01.20

Abstract

Abstract: Objective To analyze the characteristics of 229 cases of adverse drug reactions (ADR) induced by Keke tablets, and provide reference for rational use of drugs in clinic. Methods The clinical data of ADR caused by Keke tablets between January 1, 2017 and December 31, 2018 was retrospectively analyzed. Results Among the 229 cases of ADR, there were 123 males and 106 females (1.16∶1). Most of the patients were 15 to 44 years old (54.15%). Common ADR (n=162) were the most prevalent, accounting for 70.74% of the total, followed by new common ADR (n=65) that accounted for 28.38%. Most of the ADR occurred in the skin system. The main symptoms were rash (44.59%) and by pruritus (19.75%). Conclusion The characteristics of ADR induced by Keke tablets have been confirmed in this analysis, which can help standardize the clinical use of Keke tablets and revise the drug instructions so as to reduce or prevent serious ADR and to ensure safe and rational drug use.

Key words: Keke tablets, adverse drug reaction, rash, pruritus, instructions, rational drug use

CLC Number:

R994.11

QIAO Weilin, LI Haiyan. 229 cases of adverse drug reactions caused by Keke tablets[J]. Chinese Journal of Pharmacovigilance, 2022, 19(1): 91-94.

References

[1] Chinese Pharmacopoeia Commission.The Pharmacopoeia of the People's Republic of China notes for clinical use of traditional Chinese medicine preparation volume, the 2015 edition(中华人民共和国药典临床用药须知中药成方制剂卷2015年版)[M]. Beijing: China Medical Science and Technology Press, 2015, 336-337.
[2] ZHONG ZY, ZHENG JL, ZHONG HC, et al.Pharmacodynamics of Keke tablets[J]. Chinese Traditional Patent Medicine(中成药), 2013, 35(8): 1609-1614.
[3] LIN L, WANG Q, LI SY, et al.Keke tablets in the treatment of chronic bronchitis: a multicenter randomized controlled clinical trial[J].China Journal of Traditional Chinese Medicine and Pharmacy(中华中医药杂志), 2015, 30(7): 2636-2638.
[4] LIN L, WANG Q, LI SY, et al.Multiple-center, randomized, double-blinded controlled trial of Keke tablets for treatment of acute tracheobronchitis[J]. Journal of Guangzhou University of Traditional Chinese Medicine(广州中医药大学学报), 2014, 31(3): 341-342.
[5] ZHONG LM.MAHs'principal responsibilities for safety risk during the whole-life cycle of drugs[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2019, 16(11): 666-669.
[6] WANG CZ, CHEN XB, LIU XM, et al.ADR monitoring in pharmaceutical manufacturers under the background of marketing authorization holder system[J].Anhui Medical and Pharmaceutical Journal(安徽医药), 2020, 24(5): 1056-1060.
[7] CAO JY, SHU CZ, WEN XP.Analysis of the usage of Chinese patent medicine[J]. Chin J of Clinical Rational Drug Use(临床合理用药),2020, 13(1): 169-171.
[8] Chinese Pharmacopoeia Commission.The Pharmacopoeia of the People's Republic of China notes for Clinical Use Of Traditional Chinese Medicine Decoction Pieces Volume, the 2015 edition(中华人民共和国药典临床用药须知中药成方制剂卷2015年版)[M]. Beijing: China Medical Science and Technology Press, 2015: 74-78.
[9] ZHANG ZB.A case of ephedrine caused a sharp increase in blood pressure[J]. Sichuan Medical Journal(四川医药),2001, 22(12): 1107.
[10] ZHAN ZL.A case of severe hypertension induced by ephedrine in Parkinson's disease[J]. Inner Mongolia Med J(内蒙古医学杂志),2010, 42(4): 492.
[11] PAN GH, SUN XR.The safety evaluation of ephedra and its preparation aboard[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2007, 4(2): 111-117.
[12] ZHANG CY, CHENG RZ, WANG T.Research status of pharmaco-dynamic substance basis and safety of ephedra[J]. Hubei Journal of TCM(湖北中医杂志), 2018, 40(2): 58-61.
[13] ZHAO TT, ZHAO JZ.Considerations of standardize domestic approved drug package inserts[J]. Chin J Clin Pharmacol(中国临床药理学杂志), 2020, 36(14): 2153-2155.
[14] WANG Y, ZOU Z, LI F.Analysis of 159 ADR reports induced by Chinese patent medicine[J]. Anhui Medical and Pharmaceutical Journal(安徽医药), 2019, 23(11): 2320-2323.
[15] WU SF, JIN Y, CHANG H, et al.Drug risk communication in the European Union and United States between regulators and the public[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2020, 17(2): 87-92.
[16] HOU HJ, WANG L, LI XM.Current situation, existing problems and countermeasures of drug package inserts of Chinese traditional patent medicine[J]. China Food & Drug Administration Magazine(中国食品药品监管), 2020(2): 32-39.